Roblitinib, also known as FGF401, is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, FGF401 binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.
FGFR Inhibitors Related Products:
Infigratinib; PD173074; AZD4547; Danusertib; Brivanib alaninate; Pemigatinib; Lenvatinib; Lenvatinib mesylate; Nintedanib esylate; BLU9931; SKLB610